The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of CytomX Therapeutics, Inc. (NASDAQ: CTMX) who purchased shares between May 17, 2018 and May 13, 2020. The action, which was filed in the United States District Court for the Northern District of California, alleges that the Company violated federal securities laws.
In particular, the CytomX lawsuit alleges that (i) CytomX had downplayed issues with CX-072’s efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009’s efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until July 20, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >